cross reactivity
Concern over drug-induced hepatic injury is becoming more widespread because of the increasing use of potent drugs. Most of the drugs involved are in common use in clinical practice. For example, the problem of liver disease associated with administration of isonicotinic acid hydrazide (isoniazid), the drug of choice in the treatment and chemoprophylaxis of tuberculosis, has attracted much attention recently (1, 2). A significant increase in serum aminotransferase activities was observed in 8-10% of the patients receiving izoniazid (3, 4) even though the average incidence of reported hepatitis associated with its administration was less than 1% (1, 5) . These and related data seem to suggest that hepatic damage resulting from isoniazid administration may be more common than had previously been suspected. Although the etiology for isoniazid-induced hepatitis is unknown, drug hypersensitivity seems to be a strong possibility.
In an attempt to elucidate this question, we began a systematic study of clinical and immunological variables.
As part of this investigation, a precise, simple, specific, and sensitive radioimmunoassay was developed for detecting and measuring isoniazid concentrations in the sera of patients with and without liver damage; the sensitivity of the assay is 50 ag/liter.
By contrast, spectrophotometric methods (6-8) developed while this study was in progress are somewhat cumbersome and less sensitive. 
Materials and Methods

Materials
Production of Antiserum
Results and Discussion
A typical set of titration curves for the assessment of the affinity and titer (optimum concentration) of anti-isoniazid antibodies in a sample of rabbit antiserum is shown in Figure 2 . The equal displacement of the parallel titration curves for proportionately decreasing tracer doses of labeled isoniazid indicated that this antiserum was sensitive for the tracer dose of 5 nCi (5000 cpm) of isoniazid, which was selected for the assay because it provided a satisfactory counting rate without loss of precision; the antibody titration curve for this isoniazid concentration would be located between curves (b) and (c) in Figure 2 . The steepness of the slope of the curves and the high percentage (70 to 80%) of bound label in the regions of antibody excess are indications of the high affinity of these antibodies for the tritiated isoniazid. This antiserum was used in the assay at a dilution of 1/2000, corresponding to the midpoint of the titration curve; at this dilution this serum bound 20 to 30% of the tracer dose of 5 nCi of tritiated isoniazid. This antiserum was divided into 1-ml aliquots and stored frozen at -20 #{176}C until used.
The standard radioimmunoassay curve for isoniazid is shown in Figure 3( In experiments designed to establish the degree of crossieactivity, it was found that 100-fold higher concentrations of isonicotinic acid than isoniazid were required to inhibit to the same extent the binding of t'H]isoniazid with a given antiisoniazid antiserum (see Table 2 ).
(difference between values in columns 2 and 4) x100 Figure 3 (a), the sensitivity of the assay-that is, the minimum detectable amount of isoniazid-was 0.5 ng in the sample of 10 tl, or 50 ag/liter. The consistency of the radioimmunoassay was determined by measuring the amount of isoniazid present in "blind" serum samples.
When the concentration of isoniazid in these blind serurn samples was greater than 1 mg/liter (i.e., greater than 10 ng/10 /41), the discrepancy between the amount of isoniazid measured in the sample by the radioimmunoassay and the amount of isoniazid present was less than 6% (see Table 1 ).
The major metabolites of isoniazid are isonicotinic acid and acetylisoniazid (10). Jeanes et al. (11) have shown that the concentrations of these metabolites present in a serum or urine sample can be two-to threefold the concentration of isoniazid present. Therefore, it was necessary to establish the extent of crossreaction of these metabolites with isoniazid as 4 6 8 10 12
Time (Hours) Fig. 4 . lsoniazid in plasma: Concentration-vs.-time curves for slow and fast acetylators of isoniazid measured with the anti-isoniazid antiserum, so as to assess the degree of their interference in the radioimmunoassay.
The relative crossreactivities of these metabolites, calculated (Table  2 ) from the corresponding standard radioimmunoassay curves plotted in Figure 3 , were found to be less than the experimental error. Relative crossreactivity refers to the ratio of the concentration of isoniazid to that of the crossreacting compound required to displace 50% of bound
[3H]isoniazid in the radioimmunoassay, respectively.
We also determined crossreactivities of two other compounds:
niacinamide, which is normally present in human serum, and p-aminosalicylic acid, which is often given in conjunction with isoniazid in the treatment of tuberculosis.
As can be seen (Table 2) , there is no significant crossreaction between either of these compounds and isoniazid at a concentration expected to be present in the serum of a patient receiving a normal daily dose of the drug.
Preliminary
Clinical Studies
To conclude the development of this radioimmunoassay for isoniazid, we undertook a preliminary clinical study, which involved 14 patients currently undergoing isoniazid treatment and chemoprophylaxis for tuberculosis at the Respiratory Centre in Winnipeg.
All patients received 300 mg of isoniazid in tablet form at 0900 hours and then blood was collected 1, 2, 4, 8, and 12 h later. The radioimmunoassay was then used to determine the isoniazid concentration in the plasma prepared from these blood samples. The results of this study are shown in Table 3 . As can be seen, the peak isoniazid concentration usually occurred 1 to 2 h after isoniazid administration. Patients receiving izoniazid can be classified or phenotyped into two groups according to the hereditarily predetermined rate at which they metabolize isoniazid in the liver to bacteriologically inactive acetylisoniazid (11). The two groups are appropriately called fast or slow acetylators or inactivators of isoniazid. Figure 4 shows typical plasma isoniazid concentration vs. time curves that we obtained from this study for a fast and a slow inactivator of isoniazid. We found from these curves that patients could be best classified as to whether they were a slow or fast inactivator of isoniazid on the basis of a half-life value, t%, which measured the time it took from t = 0 (time of administration) for the isoniazid concentration in the plasma to decrease to half its maximum value. Table 4 shows the results of this classification.
